The Europe Omics Lab Services Market should witness market growth of 12.5% CAGR during the forecast period (2022-2028).
A thorough understanding of the molecules which make up a cell, tissue, or organism is provided through omics technology. They are largely focused on the non-targeted, non-biased detection of all genes (genomics), proteins (proteomics), mRNA (transcriptomics), and metabolites (metabolomics) in a particular biological sample. The combination of these methodologies is known as system biology, and this may also be referred to as advanced biology.
Experiments in systems biology and omics are distinct from conventional investigations, which are mostly hypothesis-driven. While no hypothesis is specified or mandated in systems biology studies, all data are collected and evaluated to produce a hypothesis that may be tested further. These experiments use holistic methodologies instead. Omics technology may be used to better understand not just physiological processes that occur naturally but also those that occur in illness, where it can be used for prognostication, diagnosis, and screening. It can also be used to better understand the genesis of diseases.
For the study of the transcriptome, many techniques, including microarrays, real-time polymerase chain reaction, RNA sequencing, RNA interference, SAGE, expressed sequence tag (EST)-based technologies, and others, have been developed.
Lung cancer is the leading cause of mortality in Europe, responsible for roughly 20% of all cancer deaths and 3.2 million disability-adjusted life years lost each year. Lung cancer affects more than a quarter of those under the age of 60. Seven out of every eight patients die after five years of diagnosis, given current breakthroughs in surgery, chemotherapy, and radiotherapy. New findings in knowing the biology of lung cancer, on the other hand, have resulted in the development of potential novel targeted medicines.
The Germany market dominated the Europe Omics Lab Services Market by Country in 2021; thereby, achieving a market value of $9.2 billion by 2028. The UK market is exhibiting a CAGR of 11.5% during (2022-2028). Additionally, The France market would experience a CAGR of 13.3% during (2022-2028).
Based on Business, the market is segmented into Diagnostic Labs, Research Institutes, and Hospitals. Based on End-use, the market is segmented into Cancer, Pharmaco, Population Studies & Genealogy, Reproductive, Skincare, Nutrition, Vitamin & Supplements, and Forensics & Others. Based on Type, the market is segmented into Proteomics, Transcriptomic, Metabolomics, Genomics, and Epigenetics. Based on Product, the market is segmented into Hardware Equipment, Testing / Lab Services, and Analytics / Interpretation. Based on Frequency of Service, the market is segmented into Continuous, Repeat, and One-off. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Illumina, Inc., BGI Group, Q2 Solutions (IQVIA), Flomics Biotech, PhenoSwitch Bioscience
A thorough understanding of the molecules which make up a cell, tissue, or organism is provided through omics technology. They are largely focused on the non-targeted, non-biased detection of all genes (genomics), proteins (proteomics), mRNA (transcriptomics), and metabolites (metabolomics) in a particular biological sample. The combination of these methodologies is known as system biology, and this may also be referred to as advanced biology.
Experiments in systems biology and omics are distinct from conventional investigations, which are mostly hypothesis-driven. While no hypothesis is specified or mandated in systems biology studies, all data are collected and evaluated to produce a hypothesis that may be tested further. These experiments use holistic methodologies instead. Omics technology may be used to better understand not just physiological processes that occur naturally but also those that occur in illness, where it can be used for prognostication, diagnosis, and screening. It can also be used to better understand the genesis of diseases.
For the study of the transcriptome, many techniques, including microarrays, real-time polymerase chain reaction, RNA sequencing, RNA interference, SAGE, expressed sequence tag (EST)-based technologies, and others, have been developed.
Lung cancer is the leading cause of mortality in Europe, responsible for roughly 20% of all cancer deaths and 3.2 million disability-adjusted life years lost each year. Lung cancer affects more than a quarter of those under the age of 60. Seven out of every eight patients die after five years of diagnosis, given current breakthroughs in surgery, chemotherapy, and radiotherapy. New findings in knowing the biology of lung cancer, on the other hand, have resulted in the development of potential novel targeted medicines.
The Germany market dominated the Europe Omics Lab Services Market by Country in 2021; thereby, achieving a market value of $9.2 billion by 2028. The UK market is exhibiting a CAGR of 11.5% during (2022-2028). Additionally, The France market would experience a CAGR of 13.3% during (2022-2028).
Based on Business, the market is segmented into Diagnostic Labs, Research Institutes, and Hospitals. Based on End-use, the market is segmented into Cancer, Pharmaco, Population Studies & Genealogy, Reproductive, Skincare, Nutrition, Vitamin & Supplements, and Forensics & Others. Based on Type, the market is segmented into Proteomics, Transcriptomic, Metabolomics, Genomics, and Epigenetics. Based on Product, the market is segmented into Hardware Equipment, Testing / Lab Services, and Analytics / Interpretation. Based on Frequency of Service, the market is segmented into Continuous, Repeat, and One-off. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Illumina, Inc., BGI Group, Q2 Solutions (IQVIA), Flomics Biotech, PhenoSwitch Bioscience
Scope of the Study
By Business
- Diagnostic Labs
- Research Institutes
- Hospitals
By End-Use
- Cancer
- Pharmaco
- Population Studies & Genealogy
- Reproductive
- Skincare
- Nutrition, Vitamin & Supplements
- Forensics & Others
By Type
- Proteomics
- Transcriptomic
- Metabolomics
- Genomics
- Epigenetics
By Product
- Hardware Equipment
- Testing / Lab Services
- Analytics / Interpretation
By Frequency of Service
- Continuous
- Repeat
- One-off
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Quest Diagnostics Incorporated
- Illumina, Inc.
- BGI Group
- Q2 Solutions (IQVIA)
- Flomics Biotech
- PhenoSwitch Bioscience
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Omics Lab Services Market, by Business
1.4.2 Europe Omics Lab Services Market, by End-Use
1.4.3 Europe Omics Lab Services Market, by Type
1.4.4 Europe Omics Lab Services Market, by Product
1.4.5 Europe Omics Lab Services Market, by Frequency of Service
1.4.6 Europe Omics Lab Services Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Omics Lab Services Market
Chapter 4. Europe Omics Lab Services Market by Business
4.1 Europe Diagnostic Labs Market by Country
4.2 Europe Research Institutes Market by Country
4.3 Europe Hospitals Market by Country
Chapter 5. Europe Omics Lab Services Market by End-Use
5.1 Europe Cancer Market by Country
5.2 Europe Pharmaco Market by Country
5.3 Europe Population Studies & Genealogy Market by Country
5.4 Europe Reproductive Market by Country
5.5 Europe Skincare Market by Country
5.6 Europe Nutrition, Vitamin & Supplements Market by Country
5.7 Europe Forensics & Others Market by Country
Chapter 6. Europe Omics Lab Services Market by Type
6.1 Europe Proteomics Market by Country
6.2 Europe Transcriptomic Market by Country
6.3 Europe Metabolomics Market by Country
6.4 Europe Genomics Market by Country
6.5 Europe Epigenetics Market by Country
Chapter 7. Europe Omics Lab Services Market by Product
7.1 Europe Hardware Equipment Market by Country
7.2 Europe Testing / Lab Services Market by Country
7.3 Europe Analytics / Interpretation Market by Country
Chapter 8. Europe Omics Lab Services Market by Frequency of Service
8.1 Europe Continuous Market by Country
8.2 Europe Repeat Market by Country
8.3 Europe One-off Market by Country
Chapter 9. Europe Omics Lab Services Market by Country
9.1 Germany Omics Lab Services Market
9.1.1 Germany Omics Lab Services Market by Business
9.1.2 Germany Omics Lab Services Market by End-Use
9.1.3 Germany Omics Lab Services Market by Type
9.1.4 Germany Omics Lab Services Market by Product
9.1.5 Germany Omics Lab Services Market by Frequency of Service
9.2 UK Omics Lab Services Market
9.2.1 UK Omics Lab Services Market by Business
9.2.2 UK Omics Lab Services Market by End-Use
9.2.3 UK Omics Lab Services Market by Type
9.2.4 UK Omics Lab Services Market by Product
9.2.5 UK Omics Lab Services Market by Frequency of Service
9.3 France Omics Lab Services Market
9.3.1 France Omics Lab Services Market by Business
9.3.2 France Omics Lab Services Market by End-Use
9.3.3 France Omics Lab Services Market by Type
9.3.4 France Omics Lab Services Market by Product
9.3.5 France Omics Lab Services Market by Frequency of Service
9.4 Russia Omics Lab Services Market
9.4.1 Russia Omics Lab Services Market by Business
9.4.2 Russia Omics Lab Services Market by End-Use
9.4.3 Russia Omics Lab Services Market by Type
9.4.4 Russia Omics Lab Services Market by Product
9.4.5 Russia Omics Lab Services Market by Frequency of Service
9.5 Spain Omics Lab Services Market
9.5.1 Spain Omics Lab Services Market by Business
9.5.2 Spain Omics Lab Services Market by End-Use
9.5.3 Spain Omics Lab Services Market by Type
9.5.4 Spain Omics Lab Services Market by Product
9.5.5 Spain Omics Lab Services Market by Frequency of Service
9.6 Italy Omics Lab Services Market
9.6.1 Italy Omics Lab Services Market by Business
9.6.2 Italy Omics Lab Services Market by End-Use
9.6.3 Italy Omics Lab Services Market by Type
9.6.4 Italy Omics Lab Services Market by Product
9.6.5 Italy Omics Lab Services Market by Frequency of Service
9.7 Rest of Europe Omics Lab Services Market
9.7.1 Rest of Europe Omics Lab Services Market by Business
9.7.2 Rest of Europe Omics Lab Services Market by End-Use
9.7.3 Rest of Europe Omics Lab Services Market by Type
9.7.4 Rest of Europe Omics Lab Services Market by Product
9.7.5 Rest of Europe Omics Lab Services Market by Frequency of Service
Chapter 10. Company Profiles
10.1 Thermo Fisher Scientific, Inc.
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 SWOT Analysis
10.2 Agilent Technologies, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Segmental and Regional Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Acquisition and Mergers:
10.3 Qiagen N.V.
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Regional Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Acquisition and Mergers:
10.4 Quest Diagnostics Incorporated
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental Analysis
10.4.4 Recent strategies and developments:
10.4.4.1 Acquisition and Mergers:
10.5 Illumina, Inc.
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Regional Analysis
10.5.4 Research & Development Expense
10.5.5 Recent strategies and developments:
10.5.5.1 Partnerships, Collaborations, and Agreements:
10.6 BGI Group
10.6.1 Company Overview
10.7 Q2 Solutions (IQVIA)
10.7.1 Company Overview
10.7.2 Recent strategies and developments:
10.7.2.1 Partnerships, Collaborations, and Agreements:
10.8 Flomics Biotech
10.8.1 Company Overview
10.9 PhenoSwitch Bioscience
10.9.1 Company Overview
10.9.2 Recent strategies and developments:
10.9.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Quest Diagnostics Incorporated
- Illumina, Inc.
- BGI Group
- Q2 Solutions (IQVIA)
- Flomics Biotech
- PhenoSwitch Bioscience
Methodology
LOADING...
